Lyme Disease Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
Approximately 6,000 participants 5 years of age and older will be enrolled in Lyme disease-endemic regions in Europe and the U.S. NEW YORK& SAINT-HERBLAIN, France--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN;... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 8, 2022 Category: Pharmaceuticals Source Type: clinical trials

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
Condition: Lyme Disease Interventions: Biological: VLA15; Other: Saline Sponsors: Pfizer; Valneva Austria GmbH Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 28, 2022 Category: Research Source Type: clinical trials

Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
Strong immunogenicity profile observed in study participants aged 5-17 years one month after the primary vaccination series Safety profile observed in pediatric participants similar to previously reported data in adult participants Pediatric... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 26, 2022 Category: Pharmaceuticals Source Type: clinical trials

The Burden of Lyme Disease (BOLD) in a Pandemic - Insights From an Online Cross-sectional and Prospective Cohort Survey
Conditions: COVID-19; Lyme Disease; COVID-19 Vaccine Intervention: Other: Cross sectional survey Sponsor: Dr. Daniel Cameron & Associates Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2022 Category: Research Source Type: clinical trials